Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses

Vaccine

Volumn 23, Issue 39, 2005, Pages 4765-4774

  Nolan, Sheila M ^a   Surman, Sonja R ^a   Amaro Carambot, Emerito ^a   Collins, Peter L ^a   Murphy, Brian R ^a   Skiadopoulos, Mario H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

L polymerase; Parainfluenza virus; Paramyxovirus

Indexed keywords

PARAINFLUENZA VACCINE; DNA DIRECTED RNA POLYMERASE; LIVE VACCINE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC STABILITY; HAMSTER; NONHUMAN; NUCLEOTIDE SEQUENCE; PARAINFLUENZA VIRUS 2; PARAMYXOVIRUS; PRIORITY JOURNAL; REVERTANT; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; CODON; GENETICS; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MOLECULAR GENETICS; MUTATION; PHYSIOLOGY; SYRIAN HAMSTER;

ADMINISTRATION, INTRANASAL; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CODON; CRICETINAE; DNA-DIRECTED RNA POLYMERASES; HUMANS; MESOCRICETUS; MOLECULAR SEQUENCE DATA; MUTATION; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 2, HUMAN; PARAMYXOVIRINAE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRUS REPLICATION;

EID: 25144455601     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.04.043     Document Type: Article

References (39)

1. Murphy BR. Current approaches to the development of vaccines effective against parainfluenza viruses. Bull World Health Organ 1988;66(3):391-7.
2. Collins PL, Murphy BR. Respiratory syncytial virus: reverse genetics and vaccine strategies. Virology 2002;296(2):204-11.
3. Skiadopoulos MH, Schmidt AC, Riggs JM, et al. Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic. J Virol 2003;77(2):1141-8.
4. Skiadopoulos MH, Surman SR, Riggs JM, Orvell C, Collins PL, Murphy BR. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology 2002;297(1):136-52.
5. Skiadopoulos MH, Surman SR, St Claire M, Elkins WR, Collins PL, Murphy BR. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation. Virology 1999;260(1):125-35.
6. Calain P, Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 1993;67(8):4822-30.
7. Vulliemoz D, Roux L. Rule of six: how does the Sendai virus RNA polymerase keep count? J Virol 2001;75(10):4506-18.
8. Kolakofsky D, Pelet T, Garcin D, Hausmann S, Curran J, Roux L. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol 1998;72(2):891-9.
9. Skiadopoulos MH, Vogel L, Riggs JM, Surman SR, Collins PL, Murphy BR. The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations. J Virol 2003;77(1):270-9.
10. Poole E, He B, Lamb RA, Randall RE, Goodbourn S. The V proteins of simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology 2002;303(1):33-46.
11. Andrejeva J, Young DF, Goodbourn S, Randall RE. Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons. J Virol 2002;76(5):2159-67.
12. Chanock RM, Murphy BR, Collins PL. Parainfluenza viruses. In: Knipe DM, Howley PM, Griffin DE, editors. Fields virology, vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1341-79.
13. Murphy BR, Collins PL. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest 2002;110(1):21-7.
14. Newman JT, Riggs JM, Surman SR, et al. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses. J Virol 2004;78(4):2017-28.
15. Skiadopoulos MH, Durbin AP, Tatem JM, et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live-attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol 1998;72(3):1762-8.
16. Skiadopoulos MH, Surman S, Tatem JM, et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 1999;73(2):1374-81.
17. Durbin AP, McAuliffe JM, Collins PL, Murphy BR. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 1999;261(2):319-30.
18. McAuliffe JM, Surman SR, Newman JT, et al. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J Virol 2004;78(4):2029-36.
19. Tao T, Davoodi F, Cho CJ, et al. A live-attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin- neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine 2000;18(14):1359-66.
20. Hall SL, Stokes A, Tierney EL, et al. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res 1992;22(3):173-84.
21. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22(22):4673-80.
22. Moeller K, Duffy I, Duprex P, et al. Recombinant measles viruses expressing altered hemagglutinin (H) genes: functional separation of mutations determining H antibody escape from neurovirulence. J Virol 2001;75(16):7612-20.
23. Newman JT, Surman SR, Riggs JM, et al. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes 2002;24(1):77-92.
24. Chanock R, Parrott R, Johnson K, Kapikian A, Bell J. Myxoviruses: parainfluenza. Am Rev Respir Dis 1963;88:152-66.
25. Skiadopoulos MH, Tao T, Surman SR, Collins PL, Murphy BR. Generation of a parainfluenza virus type 1 vaccine candidate by replacing c the HN and F glycoproteins of the live-attenuated PIV3 cp45 vacine virus with their PIV1 counterparts. Vaccine 1999;18(5-6):503-10.
26. Juhasz K, Murphy BR, Collins PL. The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination. J Virol 1999;73(6):5176-80.
27. Juhasz K, Whitehead SS, Boulanger CA, Firestone CY, Collins PL, Murphy BR. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine 1999;17(11-12):1416-24.
28. Whitehead SS, Firestone CY, Karron RA, et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 1999;73(2):871-7.
29. Garcin D, Itoh M, Kolakofsky D. A point mutation in the Sendai virus accessory C proteins attenuates virulence for mice, but not virus growth in cell culture. Virology 1997;238(2):424-31.
30. Itoh M, Isegawa Y, Hotta H, Homma M. Isolation of an avirulent mutant of Sendai virus with two amino acid mutations from a highly virulent field strain through adaptation to LLC-MK2 cells. J Gen Virol 1997;78(Pt 12):3207-15.
31. Murphy BR, Park EJ, Gottlieb P, Subbarao K. An influenza A live-attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine 1997;15(12-13):1372-8.
32. Tolpin MD, Massicot JG, Mullinix MG, et al. Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo. Virology 1981;112:505-17.
33. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000;182(5):1331-42.
34. Murphy BR, Coelingh K. Principles underlying the development and use of live-attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002;15(2):295-323.
35. Snyder MH, London WT, Maassab HF, Chanock RM, Murphy BR. A 36 nucleotide deletion mutation in the coding region of the NS1 gene of an influenza A virus RNA segment 8 specifies a temperature-dependent host range phenotype. Virus Res 1990;15(1):69-83.
36. Berkhout B, Verhoef K, van Wamel JL, Back NK. Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J Virol 1999;73(2):1138-45.
37. Carl S, Iafrate AJ, Skowronski J, Stahl-Hennig C, Kirchhoff F. Effect of the attenuating deletion and of sequence alterations evolving in vivo on simian immunodeficiency virus C8-Nef function. J Virol 1999;73(4):2790-7.
38. Durbin AP, Elkins WR, Murphy BR. African green monkeys provide a useful non-human primate model for the study of human parainfluenza virus types-1, -2, and -3 infection. Vaccine 2000;18(22):2462-9.
39. Bartlett EJ, Amaro-Carambot E, Surman SR, Newman JT, Collins PL, Murphy BR, et al. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 2005 doi:10.1016/j. vaccine.2005.04.035.